Replies to post #9890 on Momenta Pharmaceuticals, Inc. (MNTA)

[io_io]

Dew, in your post and the news release:

"including enoxaparin product revenue of $2.6 million.... Sandoz reported third quarter 2012 enoxaparin net sales of $34 million"

I thought MNTA had an 11% royalty now? The above computes to 7.65%.

"Excluding the royalty payable to MIT on enoxaparin product..."

After deduction of the MIT royalty from the $2.6m revenue, does anybody know the net MNTA had on mLov?

Wondering if there is a way that mCop could turn out better than this.

[DewDiligence]

Transcript of MNTA’s 3Q12 CC:

http://seekingalpha.com/article/988071-momenta-pharmaceuticals-ceo-discusses-q3-2012-results-earnings-call-transcript